When discussing treatment options for patients with acute leukemia, it is important to acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or chemotherapy on quality of life (QOL). We performed a cross-sectional questionnaire study that administered SF-36, FACT-Leukemia and EuroQOL5D to 524 acute leukemia survivors, to compare patientreported QOL between chemotherapy and allo-HCT, and to elucidate predictors of QOL. Patients who received chemotherapy alone had a better physical QOL than those who received allo-HCT. On the other hand, the allo-HCT group reported a better mental QOL. In the comparison of QOL in the allo-HCT patients according to the presence of GVHD at survey, patients who had GVHD symptoms experienced statistically and clinically significantly worse QOL than those who did not. In the allo-HCT patients without GVHD, the physical QOL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QOL than the chemotherapy patients. GVHD and immunosuppressive drugs at survey were strongly associated with worse QOL after allo-HCT. In the chemotherapy group, a shorter time between treatment completion and survey was significantly associated with worse QOL. Further evaluation of QOL by a longitudinal assessment with quantitative and qualitative analyses are warranted.
INTRODUCTION
Chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT) are well-established treatments for AML and ALL. Improvements in these treatment modalities [1] [2] [3] [4] [5] [6] [7] [8] have resulted in a growing number of acute leukemia survivors. Allo-HCT is a potentially curative treatment strategy that reduces the risk of relapse, however, it carries an attendant risk of significant acute complications and late effects that may lead to non-relapse mortality. [9] [10] [11] Even among survivors who overcome the primary disease without life-threatening complications, late effects such as chronic GVHD, infections, organ toxicity, secondary cancers and infertility may impair their quality of life (QOL) as demonstrated in previous studies. [12] [13] [14] [15] [16] [17] [18] [19] [20] Several studies have compared patient-reported QOL between allo-HCT and chemotherapy. [21] [22] [23] [24] [25] [26] [27] Zittoun et al. 27 performed a cross-sectional study of the EORTC-GIMEMA AML 8 A trial and compare QOL after allo-HCT, autologous HCT and chemotherapy, and reported that allo-HCT had an adverse impact on the QOL. More recent cross-sectional studies 24, 25 applied the EORTC Quality of Life Core Questionnaire (QLQ-C30) to a larger number of AML patients, and reported that patients who received allo-HCT had a significantly worse QOL. However, other studies have reported inconsistent results, because of heterogeneous diseases, a small number of patients included, and different types of questionnaires used in the studies.
Decision analysis is a statistical technique that aids medical decision making by considering not only survival time but also QOL experienced after different strategies. In previous decision analyses regarding hematologic diseases and HCT, [28] [29] [30] [31] [32] QOL estimates were determined by physicians. Therefore, the QOL-adjusted life expectancies demonstrated in these studies may not accurately reflect the QOL that patients themselves experience.
Accordingly, we conducted a cross-sectional questionnaire study to investigate patient-reported QOL in patients who had completed their treatment for acute leukemia. This study aimed to (1) compare QOL after chemotherapy alone to that after allo-HCT, (2) elucidate factors associated with QOL after treatment for acute leukemia and (3) determine QOL utility estimates from acute leukemia survivors.
SUBJECTS AND METHODS

Study design and participants
The protocol of this cross-sectional questionnaire study was approved by the Institutional Review Board at the National Cancer Center Hospital. Eligible participants were diagnosed with AML or ALL, had completed 1 treatment and were not hospitalized at survey, and were aged 20 years or more at survey. Participants were recruited between August 2011 and September 2012. This study was announced using the brochure describing the outline of the study, through patient associations, cancer advocacy organizations and out-patient clinics of hematology departments across the country. Potential participants, who voluntarily provide their name and address to the study team at the National Cancer Center Hospital, were mailed QOL measures with a consent form and a stamped and self-addressed envelope.
Participants were asked to provide information about their background (gender, and age at diagnosis and at survey by decade), disease (diagnosis, year of diagnosis/completion of therapy, whether they received chemotherapy alone or allo-HCT and disease status at survey by decade), HCTrelated factors (year of HCT, donor, conditioning, disease status at HCT, GVHD at survey and administration of immunosuppressant at survey) and social background (marital status, employment status, education and household composition). Regarding GVHD status at survey, we did not apply any established scales and participants were asked to subjectively assess the presence of symptoms related to GVHD.
QOL measures
SF-36, FACT-Leukemia and EuroQOL5D (EQ-5D) were administered to assess patient-reported QOL. In all of these scales, higher scores indicate a better QOL.
SF-36 Version 2 is a comprehensive scale that consists of a 36-item questionnaire, which assesses self-reported health for both a healthy population and patients with any disease including cancer. Use of the SF-36 normative scores for the Japanese general population enables us to compare the scores of leukemia patients with those of the general population. 33 The scale includes eight subscales: physical functioning (PF), role functioning-physical (RP), bodily pain, general health, vitality, social functioning (SF), role functioning-emotional (RE) and mental health. As summary scales, we adopted a three-component model that included a physical component summary (PCS), a mental component summary (MCS) and a role component summary (RCS). 34, 35 FACT-Leukemia Version 4.0 is a disease-specific scale that consists of a 44-item self-report questionnaire. 36 It includes the general version of the FACT (FACT-G) and a 17-item subscale that assesses concerns related to leukemia (Leukemia Subscale). FACT-G holds multiple QOL domains including physical, functional, social/family and emotional well-being. FACT-Leukemia Trial Outcome Index was derived by combining physical well-being, functional well-being and Leukemia Subscale. 37 The FACT-G total score and Leukemia Subscale score are summarized to give a total FACT-Leukemia score.
The EQ-5D consists of a descriptive system and the visual analog scale (VAS). The descriptive system consists of the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The VAS records the respondent's self-rated health on a vertical 20 cm scale with the end points labeled 'best imaginable health state' at the top and 'worst imaginable health state' at the bottom, with numeric values of 100 and 0, respectively. The VAS scores can be converted to time trade-off scores (EQ-5D index) using the Japanese VAS value sets.
Statistical analysis
Standard algorithms were used to compute total and subscale scores for SF-36, 34, 35, 38 FACT-Leukemia 36 and EQ-5D. 39 QOL scores were evaluated according to the treatment the participant received (chemotherapy alone or allo-HCT), and the allo-HCT group was further divided according to the presence of GVHD at survey. Multivariable models were constructed to examine the relationship between treatment/GVHD (chemotherapy, no GVHD after allo-HCT and with GVHD after allo-HCT) and patient-reported QOL after controlling for background covariates: age at survey (six-level scale by decade), gender, disease (AML vs ALL), time from the completion of therapy (year), employment status, marital status (married at survey vs others) and education level (university/graduate school vs others). To assess the clinical significance of findings, we used the distribution-based method using the Cohen effect size benchmark. Effect sizes of 0.2, 0.5 and 0.8 s.d. were interpreted as small, medium and large differences, respectively, in this study. 15, 40 We also conducted multivariate analyses to identify factors that were associated with QOL. In the multivariate analysis that was limited to the allo-HCT group, the covariates considered were donor (matched sibling vs others), disease status at HCT (first complete remission (CR1) vs others), presence or absence of GVHD at survey and administration of immunosuppressive drugs, in addition to the seven covariates mentioned above. Adjusted mean scores (least-squares means) of each QOL domain were estimated using the seven variables. Adjusted means for the SF-36 scores were obtained as norm-based scores (mean = 50, s.d. = 10 based on 2007 sex-and age-adjusted general Japanese population). Estimated means and 95% confidence intervals for each QOL score were compared graphically among the groups. Data were analyzed with SPSS statistical software (version 15.0; SPSS, Chicago, IL, USA).
RESULTS
Participants
Among 708 potential participants, 578 participants (82%) returned questionnaires and a consent form between August 2011 and January 2013. As shown in Figure 1 , 54 participants were excluded, including 3 who had recurrent disease at survey and 42 who completed the treatment within a year. Consequently, a total of (Table 1) . The disease was AML in 75% and ALL in 24%. Males accounted for 46% and the median patient age at survey was in the 50s. The age at diagnosis ranged from 5 years to over 70 years of age. Characteristics of social backgrounds of participants are shown in Supplementary Table 1 .
Overall, 186 participants (35%) received chemotherapy alone, including 19 who received autologous HCT, and 338 (65%) received allo-HCT. As expected, the allo-HCT group included a larger proportion of younger participants (median, allo-HCT, 40s; chemotherapy, 50s; P o0.001). The time from the completion of therapy was not significantly different between the allo-HCT (median, 5 years; range, 1-19 years) and chemotherapy groups (median, 5 years; range, 1-24 years). In the allo-HCT group, 160 participants (47%) answered that they were having GVHD symptoms at survey and 61 (16%) answered that they did not know whether they were having GVHD symptom. Among them, 113 participants (33%) were taking immunosuppressive drugs. Characteristics of allo-HCT are shown in Supplementary Table 2.
The overall rate of completion was 97% for SF-36, 96% for FACT-Leukemia and 96% for EQ-5D. The total and subscale scores of the QOL measures and the number of participants who completed each scale are shown in Supplementary Table 3 .
Comparison of patient-related QOL between allo-HCT and chemotherapy and the impact of GVHD We compared QOL among groups according to the treatment and GVHD status after controlling background variables as described in the Statistical Analysis (Table 2 and Supplementary Table 4 ). In the comparison of QOL between the allo-HCT and chemotherapy groups, chemotherapy patients had statistically significantly better physical QOL (PF, RP, PCS and RCS). On the other hand, patients who received allo-HCT experienced significantly better mental QOL (MCS and emotional well-being). These statistical differences were associated with clinical significance of 40.2 s.d. There were no significant interactions between age and type of treatment. We then divided the allo-HCT group into two groups according to the GVHD status at survey (presence of GVHD at survey, yes vs no/do Abbreviation: Allo-HCT = allogeneic hematopoietic cell transplantation. Regarding employment status, 'Employed' included regular/part-time employment and 'unemployed' included homemaker, student and innocupation. Regarding marital status, 'Married' included those who were married at survey.
Quality of life after treatment for acute leukemia S Kurosawa et al not know), and compared the three groups (chemotherapy, allo-HCT without GVHD (no GVHD) and allo-HCT with GVHD (GVHD)). In the comparison of QOL between the chemotherapy and GVHD groups, chemotherapy patients had statistically significantly better QOL in all of the domains except for subscales related to the mental/social state. These differences were associated with clinical significance of 40.2 s.d., and in domains related to physical condition, medium clinically important differences were observed (s.d.: PF, 0.6; RP, 0.5; PCS, 0.7; physical well-being, 0.6; FACT-Leukemia Trial Outcome Index, 0.5). In contrast, in the comparison between the chemotherapy and no GVHD groups, the QOL scores were generally higher in the no GVHD group. Patients who did not have GVHD symptoms at survey after allo-HCT had statistically significantly better QOL in all of the domains except for subscales related to physical/ functioning domains. These differences were associated with clinical significance of 40.2 s.d. Consequently, the GVHD group had statistically significantly worse QOL compared with the no GVHD group in all of the domains, and most of them showed medium to large clinically important differences. Analyses excluding patients who completed their treatment 10 years or longer before survey did not change these results. These results are also shown in Figure 2 as adjusted mean scores for each QOL domain.
Comparison to population normative data The mean scores (50 points) in the general population for SF-36 are shown in Figure 2 as a vertical line. Adjusted mean scores in all three groups were lower than those in the general population for PF, RP, SF, RE, PCS and RCS, which indicated that QOL related to physical/role/social functioning is generally impaired in leukemia patients regardless of treatment or state of GVHD. In comparison, the no GVHD group had higher scores for bodily pain, vitality, mental health and MCS compared with the general population. MCS scores in all three groups were higher than that in the general population.
Factors affecting patient-reported QOL after allo-HCT or chemotherapy Multivariate analyses were conducted separately in the allo-HCT and chemotherapy groups to identify factors that were associated with QOL. In the allo-HCT group, the presence of GVHD symptoms, immunosuppressive therapy, inability to return to work, male gender and younger age were significantly associated with reduced QOL in three or more domains (Table 3 and  Supplementary Table 5 ). GVHD and immunosuppressive therapy were the most robust negative factor. Unlike GVHD, the impact of immunosuppressive therapy on MCS was not significant, however, it seemed to have a stronger association on role/functioning QOL (RP and RCS). In the chemotherapy group, a shorter interval after completion of treatment, single marital status at survey and ALL were associated with a lower QOL (Table 4 and Supplementary Table 6 ). In contrast to the allo-HCT group, male gender and younger age were not adverse factors. Analyses excluding patients who completed their treatment 10 years or longer before survey did not change these results. Table 5 shows the adjusted mean scores of the EQ-5D index reported by patients. As indicated in the results shown in Table 2 and Figure 2 , the no GVHD group had a higher score than that in the chemotherapy group, and the GVHD group had the lowest score. 2007 general Japan population) were used for SF-36. Estimates represent the QOL score for the group on the left minus the score for the group on the right. Therefore, if the estimate is positive, the group on the left had a higher QOL score than the group on the right.
QOL estimates provided by patients
Quality of life after treatment for acute leukemia S Kurosawa et al DISCUSSION QOL is a multidimensional concept that includes physical, psychological and social domains. In recent years, survival rates have increased with improved treatment modalities for cancer including leukemia, and more attention has been paid to the QOL of survivors. We evaluated the health-related QOL answered by 524 survivors who had completed a treatment for acute leukemia. Many studies have been conducted to evaluate the QOL after allo-HCT. [12] [13] [14] 19, 20, [41] [42] [43] [44] [45] [46] [47] Several studies have compared the QOL between allo-HCT and chemotherapy groups. However, these results were conflicting, and few have controlled confounding backgrounds. [21] [22] [23] [24] [25] [26] [27] In a longitudinal study that assessed the QOL in patients treated with allo-HCT, autologous HCT or chemotherapy, the allo-HCT group had higher scores in global QOL, fatigue and sleep disturbance compared with the other two groups. 21 The results may be confounded by the difference in populations between the treatment groups: the allo-HCT group included only leukemia patients and the autologous HCT/chemotherapy groups included only lymphoma patients. Three studies that included AML in remission reported worse QOL in patients who received Quality of life after treatment for acute leukemia S Kurosawa et al allo-HCT. 24, 25, 27 Zittoun et al. 27 performed a cross-sectional study and showed that physical, role functioning, sexual functioning and overall QOL were significantly lower after allo-HCT than after chemotherapy. In more recent cross-sectional studies with a larger number of AML patients, allo-HCT had an adverse impact on the QOL in many of the dimensions in EORTC QLQ-C30. 24, 25 We used a comprehensive scale (SF-36) and a disease-specific scale (FACT-Leukemia), which enabled us to assess both QOL in comparison with those in general population, and QOL specifically associated with leukemia patients. In contrast, the EORTC QLQ-C30 was used in the three studies that reported a worse QOL in the allo-HCT group. 24, 25, 27 A study that compared the EORTC QLQ-C30 and the FACT-BMT indicated that these two measures showed a low correlation in emotional and social domains. 48 As the allo-HCT group in our study showed superior QOL especially in domains related to the mental state, this may partly account for the discrepancy between previous studies and ours.
Allo-HCT patients reported favorable mental states, which was consistent with a previous report. 17 This might be partly explained by post-traumatic growth, 49 which is a positive psychological change experienced as a result of a struggle with highly challenging life circumstances. A response shift might also account for the 'improvement' in QOL after allo-HCT. 15, 50 Patients may consider a QOL that was once considered poor as being acceptable or good after experiencing significant impairments in QOL. However, as this is a cross-sectional study and we did not observe the longitudinal change in QOL, we cannot prove these speculations.
In the previous decision analysis, physicians determined higher QOL estimates for the chemotherapy group than the allo-HCT group. 32, 51 The QOL estimates for 'no relapse after chemotherapy' determined by physicians using VAS ranged from 0.90 to 0.99, 32, 51 suggesting that the QOL after chemotherapy was assumed to be almost intact. However, the QOL estimates we obtained from the EQ-5D were comparable in the chemotherapy and allo-HCT groups. Slevin et al. 52 obtained responses on the same scales from doctors and patients and found that the two sets of scores were poorly correlated, suggesting that doctors could not accurately determine what the patients felt. Although physicians may be able to objectively perceive QOL related to a patient's physical function, it may be necessary to ask the patients themselves to evaluate their QOL that consists of multidimensional concepts including mental aspects.
As predictors of QOL after allo-HCT, we found that GVHD was robustly associated with a worse QOL, which is consistent with previous studies. [12] [13] [14] 19, 20, 46 We found that immunosuppressive therapy was another strong adverse factor, and it seemed have a larger impact on role/social QOL than GVHD. In this study, younger age was associated with a worse QOL especially in mental state, which is inconsistent with previous reports. 21, 24, 25, 45 We also observed a discrepant result regarding gender, 45, 53 that is, male patients treated with allo-HCT had a worse QOL in several domains related to role/social/functioning issues and general QOL. These results may be in part influenced by ethnicity, and accounted for by the patients' subjective perception of themselves not being able to do what they are supposed to do for their present age or gender.
Our findings are susceptible to several limitations. First, we did not involve physicians in this study and all of the information including the patients' medical backgrounds was provided by the patients themselves. Therefore, the results must be interpreted with caution. However, although the presence of GVHD was only subjectively determined by patients, we found a statistically and clinically significant impact of GVHD on QOL. Second, our study included patients who themselves decided to participate in the study, which hinders us from comparing background factors between responders and non-responders. The participants may be biased to those who feel physically and mentally fit enough to answer, or those who are motivated by concerns or annoying symptoms. In addition, we should note that these results are valid for patients in remission, and this is a cross-sectional study and longitudinal changes in QOL were not assessed.
In summary, physical QOL was generally worse after allo-HCT than after chemotherapy alone, especially when the patient had GVHD symptoms at survey. Allo-HCT patients without GVHD had physical QOL comparable to that in the chemotherapy group, and the mental QOL was superior to those in the chemotherapy group and the general population. These findings from patient-reported information may be useful when discussing treatment options. Further evaluation of QOL by a longitudinal assessment including quantitative and qualitative analyses are warranted. Abbreviations: allo-HCT = allogeneic hematopoietic cell transplantation; CI = confidence interval; QOL = quality of life.
